Clinical Study of ATTR-CM

Phase 4

Recruiting

• Conditions: Transthyroxine Amyloidosis Cardiomyopathy
• Interventions: Drug: ATTR-CM

• Registration Number: NCT04935021
• Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Brief Summary

In this study, patients with ATTR-CM or gene carriers were selected to study the diagnosis and treatment, and long-term follow-up was conducted.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-06-01
• Study First Submitted: 2021-06-20
• Study First Submitted QC: 2021-06-21
• Study First Posted: 2021-06-22
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-29
• Last Update Posted: 2023-01-31
• Primary Completion: 2031-06-01
• Study Completion: 2031-06-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Patients and gene carriers of ATTR-CM confirmed in the Second Affiliated Hospital of Zhejiang University School of Medicine, regardless of gender, age 18-90 years old;
• Patients who have the ability to understand the test and can cooperate with investigators

Exclusion Criteria

• Patients who unable to understand or unwilling to fill in informed consent forms or follow visitors

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
ATTR-CM	ATTR-CM	Patients or Gene carrier

Primary Outcome Measures

Name	Time	Method
Rate of cardiovascular death, myocardial infarction, and stroke	10 year	Primary Outcome

Trial Locations

Locations (1)

xiaohong University PAN; 🇨🇳 Hangzhou, Zhejiang, China